Russia has approved a single-dose version of the Sputnik V Covid-19 vaccine after it showed almost 80% efficacy, according to the state-run fund that backed its development.
The 79.4% efficacy rate of the vaccine, called Sputnik Light, is based on an analysis of real-world data rather than a standard clinical trial, and interim results from final-stage study are expected later this month, according to a statement Thursday from the Russian Direct Investment Fund. Early and mid-stage studies showed no serious adverse events, RDIF said.
One injection of Sputnik Light “significantly reduces the possibility of severe cases leading to hospitalization,” RDIF ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.